SCHEMBL3794357

SCHEMBL3794357

CC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c1CCC(=O)N1CCN(C)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 11/20 0.60
MET P08581 6/20 0.58
KDR P35968 5/20 0.58
FGFR1 P11362 4/20 0.58
PDGFRB P09619 4/20 0.58
YES1 P07947 3/20 0.58
CDK2 P24941 2/20 0.58
PTK2B Q14289 2/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
LCK P06239 2/20 0.58
EGFR P00533 2/20 0.58
PLK4 O00444 1/20 0.58
RIOK3 O14730 1/20 0.58
CASK O14936 1/20 0.58
GAK O14976 1/20 0.58
DCLK1 O15075 1/20 0.58
EPHB6 O15197 1/20 0.58
MAP3K13 O43283 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3794353 1.00 SRC (0.60) SRCMETKDRFGFR1PDGFRB
SCHEMBL147370 0.91 KDR (0.60) SRCMETKDRFGFR1PDGFRB
SCHEMBL3801007 0.88 AURKA (0.66) SRCMETKDRFGFR1PDGFRB
SCHEMBL3801013 0.88 AURKA (0.66) SRCMETKDRFGFR1PDGFRB
SCHEMBL145626 0.87 KDR (0.71) SRCMETKDRFGFR1PDGFRB
SCHEMBL146268 0.85 SRC (0.60) SRCMETKDRFGFR1PDGFRB
SCHEMBL3812985 0.85 MET (0.57) SRCMETKDRFGFR1PDGFRB
SCHEMBL12792860 0.85 SRC (0.69) SRCKDRFGFR1PDGFRBYES1
SCHEMBL3803684 0.85 SRC (0.67) SRCAURKBAURKA
SCHEMBL3803679 0.85 SRC (0.67) SRCAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897602-B2 Indolinone compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2011-03-01 US claimed
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2010-07-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179146-A1 Indolinone Compounds as Kinase Inhibitors CDK2, MAP3K19, MAP3K20 SRC 394/4885MET 1698/4885KDR 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.